Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Amortization - Intangibles (2016 - 2025)

Historic Amortization - Intangibles for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to $1.7 million.

  • Vanda Pharmaceuticals' Amortization - Intangibles fell 256.85% to $1.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $7.1 million, marking a year-over-year decrease of 356.85%. This contributed to the annual value of $7.0 million for FY2025, which is 365.74% down from last year.
  • As of Q4 2025, Vanda Pharmaceuticals' Amortization - Intangibles stood at $1.7 million, which was down 256.85% from $1.8 million recorded in Q3 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Amortization - Intangibles registered a high of $2.0 million during Q1 2024, and its lowest value of $369000.0 during Q4 2021.
  • For the 5-year period, Vanda Pharmaceuticals' Amortization - Intangibles averaged around $988900.0, with its median value being $400000.0 (2021).
  • Its Amortization - Intangibles has fluctuated over the past 5 years, first soared by 40450.0% in 2024, then crashed by 1080.28% in 2025.
  • Vanda Pharmaceuticals' Amortization - Intangibles (Quarter) stood at $369000.0 in 2021, then rose by 2.71% to $379000.0 in 2022, then soared by 151.45% to $953000.0 in 2023, then skyrocketed by 83.84% to $1.8 million in 2024, then decreased by 2.57% to $1.7 million in 2025.
  • Its Amortization - Intangibles was $1.7 million in Q4 2025, compared to $1.8 million in Q3 2025 and $1.8 million in Q2 2025.